Not recruiting
Hormone receptor positive breast cancer+1
Not recruitingRegistered drugNo placebo
Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Registered drugNo placebo
- Disease:Hormone receptor positive breast cancerHER2 positive breast cancer
- Substances:AnastrozoleAnhydrous Docetaxel+7
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Anastrozole
